Healthcare and Pharmaceutical Sector

Eli Lilly is buying AtaiBeckley, a startup developing psychedelic-based drugs for treatment-resistant depression, for $2.8 billion upfront plus up to $1 billion more if trials succeed. Think of it like this: if current antidepressants are like slowly turning up the heat on a stove, these psychedelic treatments aim to rewire the brain's circuitry quickly—potentially giving relief in a couple of doses per year instead of daily pills. The Trump administration's backing of psychedelic research and Lilly's track record with breakthrough mental health drugs (remember Prozac?) make this part of a broader industry push into therapies that work differently from anything available today.

UnitedHealth, America's largest private health insurer, reported second-quarter earnings of $6.38 per share—blowing past the $4.90 Wall Street expected—and raised its 2026 profit outlook to $19.50–$20 per share. The company is fighting sky-high medical costs (the industry's main headache for two years) by dumping unprofitable customer contracts, booting unprofitable members, and investing $1.5 billion in AI to speed up claim approvals and spot fraud. This is a controlled shrinkage strategy: lose money-losing business, keep the profitable customers, and let automation juice margins—and it's working, though executives admit this turnaround will take years.

J&J delivered a beat-and-raise earnings report (meaning it topped estimates and raised guidance), yet shares dipped anyway—a sign the market had priced in the good news already or is waiting for something more. This happens sometimes: good news is good news, but if everyone already knows the company is solid, the stock doesn't pop. The underlying business is sound enough to warrant ownership, even if today's headline didn't move the needle.